This site is intended for health professionals only
Sunday 16 June 2019
Share |

Lilly faces £830m charge over drug

US drug maker Eli Lilly and Co is to pay a $1.4 billion (£830 million) charge over an investigation into marketing practices for its schizophrenia drug Zyprexa.

The company said it was in advanced discussions to settle the investigation. It will take the charge in the third quarter, it added.

The US attorney's office for the Eastern District of Pennsylvania led the investigation, which was launched in 2004.

Zyprexa has been Lilly's top-selling drug for a number of years, over which time it has also been subject to several accusations. The company has been accused of improperly marketing the drug to patients who were not approved users, and playing down side-effects such as weight gain.

Earlier this month, Lilly announced a separate $62 million (£36 million) settlement with 32 states over past sales and marketing practices relating to Zyprexa.

Robert Armitage, Lilly's general counsel, said: "The government's investigation of Zyprexa has been ongoing for five years, and we now have a heightened sense of responsibility to all our stakeholders to intensify efforts to resolve these issues."

Copyright PA Business 2008


Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher